Ah, the stock market. A bastion of rational thought, predictable patterns, and calm, measured reactions. Or, at least, that’s what the textbooks tell us. In the era of Donald J. Trump, however, the market often resembles a particularly caffeinated toddler in a toy store – prone to sudden, dramatic shifts based on pronouncements that can, and frequently do, contradict earlier statements. The past week has been no exception, offering a masterclass in market gymnastics driven by the former (and potentially future) President’s unique brand of economic discourse.
The Tariff Tango: A Volatile Performance
Just when investors thought they had a handle on the global trade narrative, President Trump decided to re-choreograph the entire routine. Earlier this week, the air was thick with threats of “sweeping new ‘reciprocal’ tariffs on China” and even a rather specific “100% tariff on all foreign-made produced movies”. The market, ever the sensitive soul, reacted precisely as one might expect from such unambiguous declarations of economic warfare. On Friday, October 10, 2025, Trump’s threats of a 100% tariff on Chinese imports sent the S&P 500 plummeting 2.7%, marking its worst day since April, while the Dow Jones Industrial Average dropped a hefty 878 points. Safe-haven assets, naturally, soared. Gold prices, already on a tear, hit a record high above $4,300 per ounce on Thursday. Silver followed suit, touching an all-time high of $54.47 per ounce. The Japanese Yen (JPY), another traditional safe haven, also strengthened, with the USD/JPY exchange rate dipping to two-week lows.
Then, in a move that surprised absolutely no one who has been paying attention, the tune changed. On Friday, October 17, 2025, President Trump, in a Fox News interview, declared that his proposed 100% tariffs on Chinese goods would be “not sustainable”. He even confirmed plans to meet with Chinese President Xi Jinping in South Korea, a stark contrast to an earlier social media post where he saw “no reason” for such a meeting.
And just like that, the market performed its signature pirouette. Wall Street, which had been reeling from trade tensions and concerns about regional bank stability, “cruised to the finish of a winning week”. The Dow Jones Industrial Average, S&P 500, and Nasdaq Composite all closed up 0.5% on Friday, capping their best week since early August, with the Nasdaq gaining 2.1% over the five sessions. Gold, having enjoyed its moment in the sun, promptly slid over 2% from its record high to $4,211.48 per ounce, while silver slumped 5.6% to $51.20 per ounce, both on heavy profit-taking as risk appetite returned. The Yen, sensing the temporary calm, also saw the USD/JPY rebound from its earlier lows. It seems the market, much like a seasoned ballroom dancer, has learned to anticipate the abrupt changes in rhythm.
Meanwhile, chipmaker Micron Technology (MU) found itself caught in the crossfire of ongoing U.S.-China tech tensions. The company’s shares slipped approximately 4% in pre-market trading on Friday, October 17, after reports indicated it would stop selling server chips to data centers in China, a lingering effect of Beijing’s 2023 ban on its products in critical infrastructure. This highlights the persistent geopolitical risks that continue to shadow global chip suppliers, regardless of the broader tariff rhetoric. Despite this, analysts from UBS and Citi remain bullish on MU, raising price targets to $245 and $240 respectively, citing intensifying memory and storage hardware shortages driven by AI demand.
Big Pharma’s Puzzling Prescription
Beyond the trade theatrics, President Trump also ventured into the intricate world of pharmaceutical pricing, specifically targeting the highly lucrative GLP-1 drug market. On Thursday, October 16, 2025, during a White House event focused on fertility treatments, Trump announced plans for government negotiations to “lower GLP-1 drug prices”. He specifically mentioned Ozempic, referring to it as “the fat loss drug,” and stated that prices, currently around $1,000 per month, would be “much lower,” potentially even $150 out-of-pocket.
This pronouncement, delivered with characteristic certainty, sent immediate shockwaves through the pharmaceutical sector. Shares of Novo Nordisk (NVO), the maker of Ozempic and Wegovy, tumbled roughly 4% in pre-market trading on Friday, October 17, and continued to slide, falling over 6% for the day. Eli Lilly (LLY), with its competing GLP-1 drugs Mounjaro and Zepbound, also saw its stock slip approximately 4% in pre-market trading and was down 4.3% by Friday. Investors, it seems, are not amused by the prospect of drastically reduced profit margins on these blockbuster medications.
Adding to the intrigue, Dr. Mehmet Oz, the Administrator of the Centers for Medicare & Medicaid Services, later clarified that negotiations for GLP-1 drugs had “not yet begun”. This did little to quell investor jitters, as the President’s remarks were perceived as a clear signal of intent, regardless of the current negotiation status. Analysts like those at JPMorgan, while acknowledging the potential for lower prices, suggested the comments were “in line with our expectations” for price negotiations, though some in the market found the suggested price points lower than anticipated. BMO Capital Markets, conversely, viewed the negative share price reactions as “overdone,” arguing that for insured individuals already paying as low as $25/month for GLP-1 medications, any ultimate negotiated price would be more of a “headline risk versus a true fundamental change” to Lilly and Novo’s businesses. The market, however, tends to react first and ask questions later, especially when a former President starts talking about $150 weight-loss drugs.
Beyond the Balance Sheet: Arches and Airpower
Not all of President Trump’s announcements this week carried immediate, quantifiable market implications, though they certainly added to the general ambiance. For instance, the plan to build a “Paris-like arch in DC” near the Lincoln Memorial, or the declaration of “28 new B-2s but points to B-21 production surge”, while perhaps inspiring for some, didn’t exactly send defense contractor stocks soaring or construction firms scrambling for bids. Similarly, the announcement that Andrea Bocelli would sing at the White House on December 5th seemed more suited for a cultural calendar than a financial one. These pronouncements, often delivered via his preferred social media platform, Truth Social, serve as a reminder that the former President’s influence extends far beyond traditional policy channels, often creating a unique blend of political spectacle and market-moving rhetoric.
In a week that saw gold hit record highs only to retreat, major indices swing wildly, and pharmaceutical giants sweat over potential price caps, the market has once again demonstrated its remarkable ability to adapt to, or at least absorb, the unpredictable. The constant oscillation between aggressive threats and conciliatory remarks from President Trump has become a defining feature of the investment landscape, turning what should be a straightforward assessment of economic fundamentals into a high-stakes game of policy poker. Investors, it seems, must remain nimble, well-caffeinated, and perhaps possess a good sense of humor, because in this market, the only constant is change – and the occasional, perfectly timed, contradictory soundbite.
DISCLAIMER: We read Trump’s posts so you don’t have to. This is comedy meets market data, not financial advice. Not political advice either – we just like charts and chaos.
Elana Harper is a seasoned financial editor and market analyst with over a decade of experience covering global equities, economic trends, and corporate earnings. Known for her sharp insights, Elana specializes in making complex financial topics accessible to a broad audience. She now serves as the Senior Financial Editor at Stock Market Watch, where she oversees daily market coverage and political commentary.